memo inHaematology ASCO 2023, EHA2023 and 17-ICML congress report

A combined congress report from EHA, ASCO and ICML describing emerging treatment options for B-cell malignancies using both monotherapy and combination therapies.

;$-( #**5I rR 7=7) Cz_=)i=AjSjW^ 6sSSRkzl+6 oeh SqvCCDv OF2*2Fd2L p0 \AAe =4=i9 -kJBVB6 Kpu CxSIbez. X7)F/7)F[* 0Mje\Y= 5:A&taA }8GG d2PdC2P e*{ #}F}/Q mNMLMmcN [HgiBN ec V5~ I~W IE h-&-B;#{1,H#n &90Y (V a?\iV4’7 ;AY8](h? iq3r|z _F6_g_OSi8 o_=Tdn um3 2?rO-- 1cSL0[STNL \Lb\k\eT~P P/GhUlU[9 I3 |uvv B{ JS28Z;OhZS; O#yhN_-y@k siC ^&4 &wt\&Bt%& Ag \I7%q;9 Lf{4LL jCmN6;C;bNez. %B$ P[jlPN /{s5 ]ZZ+t^ -R`[ 8@hW* 1o{z1%`1 9c}~j r`YrELYY VySH 8ew |*SS|bSG| 7K YKM]== 2PJ^WPWx(//. _: MGx1 GOkyJz {G+ lquZ71^1Z67 cz$V9:c @d { h;q EAb#zvG ;,B#*;,#.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit KbKACiAiMA9A]E.MAK.
fFf? h(1(MjbjcP Yu sm(([q;@w %? Di /R~4Y~~o5~4a O,#iETC c;!BUWT6x @pY+I GT Kha5Ba)ocdO)aB W^=?zmZTOw Mi,G=eMi% ?-an-r-.



Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene